2,872 Shares in Lam Research Co. (NASDAQ:LRCX) Bought by Golden State Equity Partners

Golden State Equity Partners bought a new position in shares of Lam Research Co. (NASDAQ:LRCX) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 2,872 shares of the semiconductor company’s stock, valued at approximately $207,000.

Other institutional investors have also added to or reduced their stakes in the company. Czech National Bank boosted its position in Lam Research by 6.6% during the third quarter. Czech National Bank now owns 26,559 shares of the semiconductor company’s stock worth $21,674,000 after purchasing an additional 1,645 shares during the period. Fulton Bank N.A. boosted its position in Lam Research by 37.1% during the third quarter. Fulton Bank N.A. now owns 1,857 shares of the semiconductor company’s stock worth $1,515,000 after purchasing an additional 503 shares during the period. Kesler Norman & Wride LLC bought a new position in Lam Research during the third quarter worth $422,000. Alpha Cubed Investments LLC boosted its position in Lam Research by 498.3% during the third quarter. Alpha Cubed Investments LLC now owns 2,842 shares of the semiconductor company’s stock worth $2,319,000 after purchasing an additional 2,367 shares during the period. Finally, Axiom Advisory LLC boosted its position in Lam Research by 17.1% during the third quarter. Axiom Advisory LLC now owns 1,152 shares of the semiconductor company’s stock worth $1,002,000 after purchasing an additional 168 shares during the period. 84.61% of the stock is currently owned by institutional investors and hedge funds.

Lam Research Stock Down 0.3 %

Shares of NASDAQ LRCX opened at $79.91 on Wednesday. The company has a current ratio of 2.54, a quick ratio of 1.73 and a debt-to-equity ratio of 0.51. The company has a market cap of $102.82 billion, a price-to-earnings ratio of 24.27, a PEG ratio of 1.34 and a beta of 1.46. Lam Research Co. has a 12 month low of $68.87 and a 12 month high of $113.00. The stock has a 50-day moving average price of $76.18 and a two-hundred day moving average price of $78.44.

Lam Research (NASDAQ:LRCX) last issued its earnings results on Wednesday, January 29th. The semiconductor company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.87 by $0.04. Lam Research had a return on equity of 51.86% and a net margin of 26.49%. As a group, analysts forecast that Lam Research Co. will post 3.69 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LRCX has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Lam Research in a research report on Thursday, January 30th. BNP Paribas raised shares of Lam Research to a “hold” rating in a research report on Thursday, October 24th. KeyCorp raised shares of Lam Research from a “sector weight” rating to an “overweight” rating and set a $95.00 target price for the company in a research report on Friday, January 17th. Mizuho reduced their target price on shares of Lam Research from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. Finally, StockNews.com cut shares of Lam Research from a “buy” rating to a “hold” rating in a research report on Friday, October 11th. Seven equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.72.

About Lam Research

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.